Related Experiment Videos
Pharmacokinetics of mezlocillin in pleural fluid
Abstract:
Mezlocillin concentrations in the pleural fluid and serum of six patients with malignant pleural effusion were determined following administration of 10 g mezlocillin over 30 minutes as a rapid infusion. Thirty minutes and eight hours after the infusion had been completed, concentrations of the active ingredient in the pleural fluid were 36.44 micrograms/ml and 112 micrograms/ml respectively; in the serum the respective values were 777.89 micrograms/ml and 44.22 micrograms/ml. The concentrations of active ingredient in the pleural fluid exceed the MIC for clinically significant pathogenic germs. The elimination half-life of mezlocillin in malignant pleural effusion is prolonged.
Insights
Mezlocillin concentrations in pleural fluid exceeded the minimum inhibitory concentration for pathogens in patients with malignant pleural effusion. The drug
Area of Science:
- Pharmacokinetics
- Oncology
- Infectious Diseases
Background:
- Malignant pleural effusion presents a challenge for antibiotic penetration.
- Optimizing antibiotic therapy requires understanding drug concentrations in effusions.
Purpose of the Study:
- To determine mezlocillin concentrations in pleural fluid and serum.
- To assess the pharmacokinetic profile of mezlocillin in malignant pleural effusion.
Main Methods:
- Six patients with malignant pleural effusion received 10g of mezlocillin via rapid infusion.
- Pleural fluid and serum samples were collected at 30 minutes and 8 hours post-infusion.
- Mezlocillin concentrations were quantified using validated assays.
Main Results:
- Pleural fluid mezlocillin concentrations at 30 minutes and 8 hours were 36.44 and 112 µg/ml, respectively.
- Serum concentrations were 777.89 µg/ml at 30 minutes and 44.22 µg/ml at 8 hours.
- Concentrations in pleural fluid surpassed the minimum inhibitory concentration (MIC) for key pathogens.
Conclusions:
- Mezlocillin achieves therapeutic concentrations in malignant pleural effusion.
- The elimination half-life of mezlocillin is prolonged in this patient population.
- Mezlocillin shows potential for treating infections associated with malignant pleural effusion.